thiotepa has been researched along with Polyneuropathies in 1 studies
Thiotepa: A very toxic alkylating antineoplastic agent also used as an insect sterilant. It causes skin, gastrointestinal, CNS, and bone marrow damage. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), thiotepa may reasonably be anticipated to be a carcinogen (Merck Index, 11th ed).
Polyneuropathies: Diseases of multiple peripheral nerves simultaneously. Polyneuropathies usually are characterized by symmetrical, bilateral distal motor and sensory impairment with a graded increase in severity distally. The pathological processes affecting peripheral nerves include degeneration of the axon, myelin or both. The various forms of polyneuropathy are categorized by the type of nerve affected (e.g., sensory, motor, or autonomic), by the distribution of nerve injury (e.g., distal vs. proximal), by nerve component primarily affected (e.g., demyelinating vs. axonal), by etiology, or by pattern of inheritance.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Women with metastatic breast cancer and at least a partial response (PR) to induction chemotherapy received three separate high-dose cycles of chemotherapy with peripheral blood progenitor support and G-CSF." | 6.70 | Phase II trial of sequential high-dose chemotherapy with paclitaxel, melphalan and cyclophosphamide, thiotepa and carboplatin with peripheral blood progenitor support in women with responding metastatic breast cancer. ( Antman, K; Balmaceda, C; Donovan, D; Frederick, D; Haythe, J; Hesdorffer, CS; Kaufman, E; Nichols, G; Papadopoulos, K; Savage, D; Sharpe, E; Tiersten, A; Troxel, A; Vahdat, LT, 2002) |
| "Women with metastatic breast cancer and at least a partial response (PR) to induction chemotherapy received three separate high-dose cycles of chemotherapy with peripheral blood progenitor support and G-CSF." | 2.70 | Phase II trial of sequential high-dose chemotherapy with paclitaxel, melphalan and cyclophosphamide, thiotepa and carboplatin with peripheral blood progenitor support in women with responding metastatic breast cancer. ( Antman, K; Balmaceda, C; Donovan, D; Frederick, D; Haythe, J; Hesdorffer, CS; Kaufman, E; Nichols, G; Papadopoulos, K; Savage, D; Sharpe, E; Tiersten, A; Troxel, A; Vahdat, LT, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Vahdat, LT | 1 |
| Balmaceda, C | 1 |
| Papadopoulos, K | 1 |
| Frederick, D | 1 |
| Donovan, D | 1 |
| Sharpe, E | 1 |
| Kaufman, E | 1 |
| Savage, D | 1 |
| Tiersten, A | 1 |
| Nichols, G | 1 |
| Haythe, J | 1 |
| Troxel, A | 1 |
| Antman, K | 1 |
| Hesdorffer, CS | 1 |
1 trial available for thiotepa and Polyneuropathies
| Article | Year |
|---|---|
Phase II trial of sequential high-dose chemotherapy with paclitaxel, melphalan and cyclophosphamide, thiotepa and carboplatin with peripheral blood progenitor support in women with responding metastatic breast cancer.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Cy | 2002 |